Collagen type III alpha 1 chain (COL3A1) (COL3A1)

Collagen type III alpha 1 chain (COL3A1) is a major fibrillar collagen that provides essential structural integrity and elasticity to various tissues, including the skin, blood vessels, and internal organs [1, 2]. It is synthesized by fibroblasts as a procollagen precursor and plays a critical role during the early stages of wound healing and embryonic development [1]. In the pharmaceutical and aesthetic industries, the synthesis of Collagen type III is a key target for skin rejuvenation therapies, where agents like retinoids and peptides are used to stimulate its production to improve skin texture [3]. Conversely, the pathological over-accumulation of Collagen type III is a central feature of tissue fibrosis in the liver, lungs, and kidneys, making its synthesis a target for anti-fibrotic drugs like pirfenidone [4, 5]. Mutations in the COL3A1 gene lead to vascular Ehlers-Danlos syndrome, a life-threatening condition characterized by the fragility of hollow organs and blood vessels [3]. Monitoring Collagen type III synthesis through biomarkers like PIIINP is clinically significant for assessing the progression of fibrotic diseases and the efficacy of therapeutic interventions [4].

Other names

Alpha-1 type III collagenProcollagen type IIIEDS4AFibrillar collagenEDSVASC

Stimulation of fibroblast-mediated collagen production via TGF-beta pathway activation; inhibition of pro-fibrotic signaling to reduce extracellular matrix deposition; regulation of post-translational hydroxylation by prolyl 4-hydroxylase.